Loading…
2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals
Background Healthy People 2020 aim to reduce fatal atherosclerotic cardiovascular disease (ASCVD) by 20%, which translates into 310 000 fewer events annually assuming proportional reduction in fatal and nonfatal ASCVD. We estimated preventable ASCVD events by implementing the American College of Car...
Saved in:
| Published in: | Journal of the American Heart Association 2016-08, Vol.5 (8), p.n/a |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5058-1c10bca88e96662c0635ec372acbebd01524b49e76e19f9124e946c904e7f33d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5058-1c10bca88e96662c0635ec372acbebd01524b49e76e19f9124e946c904e7f33d3 |
| container_end_page | n/a |
| container_issue | 8 |
| container_start_page | |
| container_title | Journal of the American Heart Association |
| container_volume | 5 |
| creator | Egan, Brent M. Li, Jiexiang White, Kellee Fleming, Douglas O. Connell, Kenneth Hernandez, German T. Jones, Daniel W. Ferdinand, Keith C. Sinopoli, Angelo |
| description | Background
Healthy People 2020 aim to reduce fatal atherosclerotic cardiovascular disease (ASCVD) by 20%, which translates into 310 000 fewer events annually assuming proportional reduction in fatal and nonfatal ASCVD. We estimated preventable ASCVD events by implementing the American College of Cardiology/American Heart Association (ACC/AHA) 2013 Cholesterol Guideline in all statin‐eligible adults. Absolute risk reduction (ARR) and number needed‐to‐treat (NNT) were calculated.
Methods and Results
National Health and Nutrition Examination Survey data for 2007–2012 were analyzed for adults aged 21 to 79 years and extrapolated to the US population. Literature‐guided assumptions were used including (1) low‐density lipoprotein cholesterol falls 33% with moderate‐intensity statins and 51% with high‐intensity statins; (2) for each 39 mg/dL decline in low‐density lipoprotein cholesterol, 10‐year ASCVD10 risk would fall 21% when ASCVD10 risk was ≥20% and 33% when ASCVD10 risk was |
| doi_str_mv | 10.1161/JAHA.116.003558 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cc37d8937c704013b1cb40695872cbb8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cc37d8937c704013b1cb40695872cbb8</doaj_id><sourcerecordid>1813629272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5058-1c10bca88e96662c0635ec372acbebd01524b49e76e19f9124e946c904e7f33d3</originalsourceid><addsrcrecordid>eNqFkU1vEzEQhlcIRKvSMzfkI5c0_l77ghQtkARVogc4W17vbOPKWQc7G5R_j5ctVXvClxnb7zwez1tV7wm-IUSS5bfVZjVlNxgzIdSr6pJiXi-0Vvj1s_yius75AZclac2Efltd0FpwxrC8rDLFhKFV0ywLDDW7GCAfIcWA1qPvIPgBkB06tN0fgnf26OOQUR8T2oANx90Z3UE8BEAUU4wamzofTza7MdiEPvsMNgO6S3CCYSpF62hDfle96UuA68d4Vf38-uVHs1ncfl9vm9Xtwgks1II4gltnlQItpaQOSybAsZpa10LbYSIob7mGWgLRvSaUg-bSacyh7hnr2FW1nbldtA_mkPzeprOJ1pu_BzHdG5uO3gUwrnA7pVntaszLRFriWo6lFqqmrm1VYX2aWYex3UPnyn-SDS-gL28GvzP38WTE1KfiBfDxEZDir7EM2ex9dhCCHSCO2RBFmKSa1rRIl7PUpZhzgv7pGYLN5LyZnJ8yMztfKj487-5J_8_nIhCz4LcPcP4fb9ozIqlifwC-OLc5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1813629272</pqid></control><display><type>article</type><title>2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>PubMed Central</source><creator>Egan, Brent M. ; Li, Jiexiang ; White, Kellee ; Fleming, Douglas O. ; Connell, Kenneth ; Hernandez, German T. ; Jones, Daniel W. ; Ferdinand, Keith C. ; Sinopoli, Angelo</creator><creatorcontrib>Egan, Brent M. ; Li, Jiexiang ; White, Kellee ; Fleming, Douglas O. ; Connell, Kenneth ; Hernandez, German T. ; Jones, Daniel W. ; Ferdinand, Keith C. ; Sinopoli, Angelo</creatorcontrib><description>Background
Healthy People 2020 aim to reduce fatal atherosclerotic cardiovascular disease (ASCVD) by 20%, which translates into 310 000 fewer events annually assuming proportional reduction in fatal and nonfatal ASCVD. We estimated preventable ASCVD events by implementing the American College of Cardiology/American Heart Association (ACC/AHA) 2013 Cholesterol Guideline in all statin‐eligible adults. Absolute risk reduction (ARR) and number needed‐to‐treat (NNT) were calculated.
Methods and Results
National Health and Nutrition Examination Survey data for 2007–2012 were analyzed for adults aged 21 to 79 years and extrapolated to the US population. Literature‐guided assumptions were used including (1) low‐density lipoprotein cholesterol falls 33% with moderate‐intensity statins and 51% with high‐intensity statins; (2) for each 39 mg/dL decline in low‐density lipoprotein cholesterol, 10‐year ASCVD10 risk would fall 21% when ASCVD10 risk was ≥20% and 33% when ASCVD10 risk was <20%; and (3) either all statin‐eligible untreated adults or all with ASCVD10 risk ≥7.5% would receive statins. Of 175.9 million adults aged 21 to 79 years not taking statins, 44.8 million (25.5%) were statin eligible. Treating all statin‐eligible adults would prevent an estimated 243 589 ASCVD events annually (ARR 5.4%, 10‐year NNT 18). Treating all statin‐eligible adults with ASCVD10 risk ≥7.5% reduces the number treated to 32.2 million (28.2% fewer), whereas ASCVD events prevented annually fall only 10.5% to 217 974 (6.8% ARR, NNT 15).
Conclusions
Implementing the ACC/AHA 2013 Cholesterol Guideline in all untreated, statin‐eligible adults could achieve ≈78% of the Healthy People 2020 ASCVD prevention goal. Most of the benefit is attained by individuals with 10‐year ASCVD risk ≥7.5%.</description><identifier>ISSN: 2047-9980</identifier><identifier>EISSN: 2047-9980</identifier><identifier>DOI: 10.1161/JAHA.116.003558</identifier><identifier>PMID: 27543306</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Adult ; Aged ; Anticholesteremic Agents - therapeutic use ; Atherosclerosis - prevention & control ; cardiovascular disease ; cholesterol ; Cholesterol, LDL - drug effects ; Cholesterol, LDL - metabolism ; epidemiology ; Female ; Goals ; guideline ; Healthy People Programs ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - prevention & control ; Male ; Middle Aged ; Numbers Needed To Treat ; Original Research ; Practice Guidelines as Topic ; Primary Prevention ; Secondary Prevention ; statin ; Young Adult</subject><ispartof>Journal of the American Heart Association, 2016-08, Vol.5 (8), p.n/a</ispartof><rights>2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5058-1c10bca88e96662c0635ec372acbebd01524b49e76e19f9124e946c904e7f33d3</citedby><cites>FETCH-LOGICAL-c5058-1c10bca88e96662c0635ec372acbebd01524b49e76e19f9124e946c904e7f33d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015284/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015284/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11560,27922,27923,46050,46474,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27543306$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Egan, Brent M.</creatorcontrib><creatorcontrib>Li, Jiexiang</creatorcontrib><creatorcontrib>White, Kellee</creatorcontrib><creatorcontrib>Fleming, Douglas O.</creatorcontrib><creatorcontrib>Connell, Kenneth</creatorcontrib><creatorcontrib>Hernandez, German T.</creatorcontrib><creatorcontrib>Jones, Daniel W.</creatorcontrib><creatorcontrib>Ferdinand, Keith C.</creatorcontrib><creatorcontrib>Sinopoli, Angelo</creatorcontrib><title>2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals</title><title>Journal of the American Heart Association</title><addtitle>J Am Heart Assoc</addtitle><description>Background
Healthy People 2020 aim to reduce fatal atherosclerotic cardiovascular disease (ASCVD) by 20%, which translates into 310 000 fewer events annually assuming proportional reduction in fatal and nonfatal ASCVD. We estimated preventable ASCVD events by implementing the American College of Cardiology/American Heart Association (ACC/AHA) 2013 Cholesterol Guideline in all statin‐eligible adults. Absolute risk reduction (ARR) and number needed‐to‐treat (NNT) were calculated.
Methods and Results
National Health and Nutrition Examination Survey data for 2007–2012 were analyzed for adults aged 21 to 79 years and extrapolated to the US population. Literature‐guided assumptions were used including (1) low‐density lipoprotein cholesterol falls 33% with moderate‐intensity statins and 51% with high‐intensity statins; (2) for each 39 mg/dL decline in low‐density lipoprotein cholesterol, 10‐year ASCVD10 risk would fall 21% when ASCVD10 risk was ≥20% and 33% when ASCVD10 risk was <20%; and (3) either all statin‐eligible untreated adults or all with ASCVD10 risk ≥7.5% would receive statins. Of 175.9 million adults aged 21 to 79 years not taking statins, 44.8 million (25.5%) were statin eligible. Treating all statin‐eligible adults would prevent an estimated 243 589 ASCVD events annually (ARR 5.4%, 10‐year NNT 18). Treating all statin‐eligible adults with ASCVD10 risk ≥7.5% reduces the number treated to 32.2 million (28.2% fewer), whereas ASCVD events prevented annually fall only 10.5% to 217 974 (6.8% ARR, NNT 15).
Conclusions
Implementing the ACC/AHA 2013 Cholesterol Guideline in all untreated, statin‐eligible adults could achieve ≈78% of the Healthy People 2020 ASCVD prevention goal. Most of the benefit is attained by individuals with 10‐year ASCVD risk ≥7.5%.</description><subject>Adult</subject><subject>Aged</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Atherosclerosis - prevention & control</subject><subject>cardiovascular disease</subject><subject>cholesterol</subject><subject>Cholesterol, LDL - drug effects</subject><subject>Cholesterol, LDL - metabolism</subject><subject>epidemiology</subject><subject>Female</subject><subject>Goals</subject><subject>guideline</subject><subject>Healthy People Programs</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypercholesterolemia - prevention & control</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Numbers Needed To Treat</subject><subject>Original Research</subject><subject>Practice Guidelines as Topic</subject><subject>Primary Prevention</subject><subject>Secondary Prevention</subject><subject>statin</subject><subject>Young Adult</subject><issn>2047-9980</issn><issn>2047-9980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>DOA</sourceid><recordid>eNqFkU1vEzEQhlcIRKvSMzfkI5c0_l77ghQtkARVogc4W17vbOPKWQc7G5R_j5ctVXvClxnb7zwez1tV7wm-IUSS5bfVZjVlNxgzIdSr6pJiXi-0Vvj1s_yius75AZclac2Efltd0FpwxrC8rDLFhKFV0ywLDDW7GCAfIcWA1qPvIPgBkB06tN0fgnf26OOQUR8T2oANx90Z3UE8BEAUU4wamzofTza7MdiEPvsMNgO6S3CCYSpF62hDfle96UuA68d4Vf38-uVHs1ncfl9vm9Xtwgks1II4gltnlQItpaQOSybAsZpa10LbYSIob7mGWgLRvSaUg-bSacyh7hnr2FW1nbldtA_mkPzeprOJ1pu_BzHdG5uO3gUwrnA7pVntaszLRFriWo6lFqqmrm1VYX2aWYex3UPnyn-SDS-gL28GvzP38WTE1KfiBfDxEZDir7EM2ex9dhCCHSCO2RBFmKSa1rRIl7PUpZhzgv7pGYLN5LyZnJ8yMztfKj487-5J_8_nIhCz4LcPcP4fb9ozIqlifwC-OLc5</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Egan, Brent M.</creator><creator>Li, Jiexiang</creator><creator>White, Kellee</creator><creator>Fleming, Douglas O.</creator><creator>Connell, Kenneth</creator><creator>Hernandez, German T.</creator><creator>Jones, Daniel W.</creator><creator>Ferdinand, Keith C.</creator><creator>Sinopoli, Angelo</creator><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>201608</creationdate><title>2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals</title><author>Egan, Brent M. ; Li, Jiexiang ; White, Kellee ; Fleming, Douglas O. ; Connell, Kenneth ; Hernandez, German T. ; Jones, Daniel W. ; Ferdinand, Keith C. ; Sinopoli, Angelo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5058-1c10bca88e96662c0635ec372acbebd01524b49e76e19f9124e946c904e7f33d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Atherosclerosis - prevention & control</topic><topic>cardiovascular disease</topic><topic>cholesterol</topic><topic>Cholesterol, LDL - drug effects</topic><topic>Cholesterol, LDL - metabolism</topic><topic>epidemiology</topic><topic>Female</topic><topic>Goals</topic><topic>guideline</topic><topic>Healthy People Programs</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypercholesterolemia - prevention & control</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Numbers Needed To Treat</topic><topic>Original Research</topic><topic>Practice Guidelines as Topic</topic><topic>Primary Prevention</topic><topic>Secondary Prevention</topic><topic>statin</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Egan, Brent M.</creatorcontrib><creatorcontrib>Li, Jiexiang</creatorcontrib><creatorcontrib>White, Kellee</creatorcontrib><creatorcontrib>Fleming, Douglas O.</creatorcontrib><creatorcontrib>Connell, Kenneth</creatorcontrib><creatorcontrib>Hernandez, German T.</creatorcontrib><creatorcontrib>Jones, Daniel W.</creatorcontrib><creatorcontrib>Ferdinand, Keith C.</creatorcontrib><creatorcontrib>Sinopoli, Angelo</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Free Archive</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of the American Heart Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Egan, Brent M.</au><au>Li, Jiexiang</au><au>White, Kellee</au><au>Fleming, Douglas O.</au><au>Connell, Kenneth</au><au>Hernandez, German T.</au><au>Jones, Daniel W.</au><au>Ferdinand, Keith C.</au><au>Sinopoli, Angelo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals</atitle><jtitle>Journal of the American Heart Association</jtitle><addtitle>J Am Heart Assoc</addtitle><date>2016-08</date><risdate>2016</risdate><volume>5</volume><issue>8</issue><epage>n/a</epage><issn>2047-9980</issn><eissn>2047-9980</eissn><abstract>Background
Healthy People 2020 aim to reduce fatal atherosclerotic cardiovascular disease (ASCVD) by 20%, which translates into 310 000 fewer events annually assuming proportional reduction in fatal and nonfatal ASCVD. We estimated preventable ASCVD events by implementing the American College of Cardiology/American Heart Association (ACC/AHA) 2013 Cholesterol Guideline in all statin‐eligible adults. Absolute risk reduction (ARR) and number needed‐to‐treat (NNT) were calculated.
Methods and Results
National Health and Nutrition Examination Survey data for 2007–2012 were analyzed for adults aged 21 to 79 years and extrapolated to the US population. Literature‐guided assumptions were used including (1) low‐density lipoprotein cholesterol falls 33% with moderate‐intensity statins and 51% with high‐intensity statins; (2) for each 39 mg/dL decline in low‐density lipoprotein cholesterol, 10‐year ASCVD10 risk would fall 21% when ASCVD10 risk was ≥20% and 33% when ASCVD10 risk was <20%; and (3) either all statin‐eligible untreated adults or all with ASCVD10 risk ≥7.5% would receive statins. Of 175.9 million adults aged 21 to 79 years not taking statins, 44.8 million (25.5%) were statin eligible. Treating all statin‐eligible adults would prevent an estimated 243 589 ASCVD events annually (ARR 5.4%, 10‐year NNT 18). Treating all statin‐eligible adults with ASCVD10 risk ≥7.5% reduces the number treated to 32.2 million (28.2% fewer), whereas ASCVD events prevented annually fall only 10.5% to 217 974 (6.8% ARR, NNT 15).
Conclusions
Implementing the ACC/AHA 2013 Cholesterol Guideline in all untreated, statin‐eligible adults could achieve ≈78% of the Healthy People 2020 ASCVD prevention goal. Most of the benefit is attained by individuals with 10‐year ASCVD risk ≥7.5%.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>27543306</pmid><doi>10.1161/JAHA.116.003558</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9980 |
| ispartof | Journal of the American Heart Association, 2016-08, Vol.5 (8), p.n/a |
| issn | 2047-9980 2047-9980 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_cc37d8937c704013b1cb40695872cbb8 |
| source | Open Access: Wiley-Blackwell Open Access Journals; PubMed Central |
| subjects | Adult Aged Anticholesteremic Agents - therapeutic use Atherosclerosis - prevention & control cardiovascular disease cholesterol Cholesterol, LDL - drug effects Cholesterol, LDL - metabolism epidemiology Female Goals guideline Healthy People Programs Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - prevention & control Male Middle Aged Numbers Needed To Treat Original Research Practice Guidelines as Topic Primary Prevention Secondary Prevention statin Young Adult |
| title | 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T23%3A21%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2013%20ACC/AHA%20Cholesterol%20Guideline%20and%20Implications%20for%20Healthy%20People%202020%20Cardiovascular%20Disease%20Prevention%20Goals&rft.jtitle=Journal%20of%20the%20American%20Heart%20Association&rft.au=Egan,%20Brent%20M.&rft.date=2016-08&rft.volume=5&rft.issue=8&rft.epage=n/a&rft.issn=2047-9980&rft.eissn=2047-9980&rft_id=info:doi/10.1161/JAHA.116.003558&rft_dat=%3Cproquest_doaj_%3E1813629272%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5058-1c10bca88e96662c0635ec372acbebd01524b49e76e19f9124e946c904e7f33d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1813629272&rft_id=info:pmid/27543306&rfr_iscdi=true |